RT Journal Article SR Electronic T1 Systematic investigation of allelic regulatory activity of schizophrenia-associated common variants JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.09.15.22279954 DO 10.1101/2022.09.15.22279954 A1 McAfee, Jessica C. A1 Lee, Sool A1 Lee, Jiseok A1 Bell, Jessica L. A1 Krupa, Oleh A1 Davis, Jessica A1 Insigne, Kimberly A1 Bond, Marielle L. A1 Phanstiel, Douglas H. A1 Love, Michael I. A1 Stein, Jason L. A1 Kosuri, Sriram A1 Won, Hyejung YR 2022 UL http://medrxiv.org/content/early/2022/09/17/2022.09.15.22279954.abstract AB Genome-wide association studies (GWAS) have successfully identified 145 genomic regions that contribute to schizophrenia risk, but linkage disequilibrium (LD) makes it challenging to discern causal variants. Computational finemapping prioritized thousands of credible variants, ∼98% of which lie within poorly characterized non-coding regions. To functionally validate their regulatory effects, we performed a massively parallel reporter assay (MPRA) on 5,173 finemapped schizophrenia GWAS variants in primary human neural progenitors (HNPs). We identified 439 variants with allelic regulatory effects (MPRA-positive variants), with 71% of GWAS loci containing at least one MPRA-positive variant. Transcription factor binding had modest predictive power for predicting the allelic activity of MPRA-positive variants, while GWAS association, finemap posterior probability, enhancer overlap, and evolutionary conservation failed to predict MPRA-positive variants. Furthermore, 64% of MPRA-positive variants did not exhibit eQTL signature, suggesting that MPRA could identify yet unexplored variants with regulatory potentials. MPRA-positive variants differed from eQTLs, as they were more frequently located in distal neuronal enhancers. Therefore, we leveraged neuronal 3D chromatin architecture to identify 272 genes that physically interact with MPRA-positive variants. These genes annotated by chromatin interactome displayed higher mutational constraints and regulatory complexity than genes annotated by eQTLs, recapitulating a recent finding that eQTL- and GWAS-detected variants map to genes with different properties. Finally, we propose a model in which allelic activity of multiple variants within a GWAS locus can be aggregated to predict gene expression by taking chromatin contact frequency and accessibility into account. In conclusion, we demonstrate that MPRA can effectively identify functional regulatory variants and delineate previously unknown regulatory principles of schizophrenia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the PsychENCODE consortium (U01MH122509, H.W. and J.L.S.), the IGVF consortium (UM1HG012003, H.W. and M.I.L.), the National Institute of General Medical Sciences (5T32GM067553, S.L; 5T32GM135128, J.C.M. and M.B.), the NIH New Innovator Award from the National Institute of Mental Health (DP2MH122403, H.W.), and the NARSAD Young Investigator Award from the Brain and Behavior Research Foundation (H.W.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human neural progenitors were acquired from the human fetal tissue obtained from the UCLA Gene and Cell Therapy Core according to IRB guidelines following voluntary termination of pregnancy. This study was performed under the auspices of the UCLA Office of Human Research Protection, which determined that it was exempt because samples are anonymous pathological specimens. Full informed consent was obtained from all of the parent donors.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data are available via the Gene Expression Omnibus under the accession number GSE211045.